Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Lung Diseases 1Esophageal Squamous Cell Carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Injections 13toripalimab 12pembrolizumab 4atezolizumab 4Gemcitabine 4Carboplatin 4Cisplatin 3trastuzumab deruxtecan 2tislelizumab 2spartalizumab 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Albumin-Bound Paclitaxel 2talazoparib 1sintilimab 1penpulimab 1olaparib 1niraparib 1nedaplatin 1mirdametinib 1enfortumab vedotin 1conteltinib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Leucovorin 1Letrozole 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Solid Tumor × Immunotherapy × Clear all
NCT06173219 2025-02-27

Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.

China-Japan Friendship Hospital

Phase 1/2 Recruiting
38 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡